Phase I study of an oral formulation of ZD9331 administered daily for 28 days

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1859-1865

  Sawyer, Michael B ^a   Ratain, Mark J ^a   Bertucci, Donna ^a   Smith, Robert P ^a   Schilsky, Richard L ^a   Vogelzang, Nicholas J ^a   Shulman, Keith ^a   Douglass, Edwin C ^a   Fleming, Gini F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLEVITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG FORMULATION; ENZYME SUBSTRATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; ADULT; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; QUINAZOLINES; THROMBOCYTOPENIA;

EID: 0038134991     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.148     Document Type: Article

References (19)

1. Hillman RS: Hematopoietic agents: Growth factors, minerals and vitamins, in Hardman JG, Limbird LE, Molinoff PB, et al (eds): Goodman and Gilman's Pharmacological Basis of Therapeutics (ed 9). New York, NY, McGraw-Hill, 1996, pp 1311-1340
2. Vest S, Bork E, Hansen HH: A phase I evaluation of N10-propargyl-5,8- dideazafolic acid. Eur J Cancer Clin Oncol 24:201-204, 1988
3. Jodrell DI, Newell DR, Morgan SE, et al: The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br J Cancer 64:833-838, 1991
4. Clarke SJ, Hanwell J, de Boer M, et al: Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14:1495-1503, 1996
5. Blackledge G: New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed (Tomudex). Br J Cancer 77:29-37, 1998 (suppl)
6. Jackman AL, Boyle FT, Harrap KR: Tomudex (ZD1694): From concept to care, a programme in rational drug discovery. Invest New Drugs 14:305-316, 1996
7. Pizzorno G, Mini E, Coronnello M, et al: Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 48:2149-2155, 1988
8. Rhee MS, Wang Y, Nair MG, et al: Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 53:2227-2230, 1993 (suppl)
9. Jackman AL, Kimbell R, Brown M, et al: The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv Exp Med Biol 370:185-188, 1994
10. Jackman AL, Kimbell R, Aherne GW, et al: Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3:911-921, 1997
11. Goh BC, Ratain MJ, Bertucci D, et al: Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol 19:1476-1484, 2001
12. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
13. Mick R, Ratain MJ: Statistical approaches to pharmacodynamic modeling: Motivations, methods, and misperceptions. Cancer Chemother Pharmacol 33:1-9, 1993
14. de Jonge MJ, Punt CJ, Sparreboom A, et al: Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 20:1923-1931, 2002
15. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596-602, 1985
16. McAdam B, Smith T, Love WC, et al: Lactate dehydrogenase levels during MACOP-B chemotherapy for non-Hodgkin's lymphoma. Med Oncol Tumor Pharmacother 10:95-101, 1993
17. Maruyama F, Ezaki K, Okamoto M, et al: Increased blood cell destruction during vigorous regeneration of bone marrow after intensive chemotherapy for non-Hodgkin lymphoma. Eur J Cancer 29A:1499, 1993
18. Jackman AL, Mitchell F, Lynn S, et al: Plasma 2-′deoxyuridine (dUrd) as a surrogate market of thymidylate synthase (TS) inhibition in patients treated with ZD9331. Proc Am Soc Clin Oncol 18:171a, 1999 (abstr 654)
19. Mitchell F, Lynn S, Jackman AL: Modified high-performance liquid chromatography assay for the measurement of 2′-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs. J Chromatogr B Biomed Sci Appl 744:351-358, 2000